Collection of Blood From Patients With Cancer
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.
Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Collection of Blood, Tissue and Urine From Patients With Cancer|
- Analyze tissue, urine, saliva, and blood components, which include serum, leukocytes, and circulating tumor cells (cTC), of patients with cancer [ Time Frame: On-going ] [ Designated as safety issue: No ]
- Assess the immunologic status of patients with muscle invasive bladder cancer at baseline during and after chemotherapy and post surgery to determine the best time to initiate concurrent or sequential immunotherapy [ Time Frame: On-going ] [ Designated as safety issue: No ]
- Correlate the immunologic subsets in blood with those present in tumor tissue [ Time Frame: On-going ] [ Designated as safety issue: No ]
- Assess the differences in immunologic subsets found with standard gemcitabine and cisplatin with those in dose dense gemcitabine and cisplatin [ Time Frame: On-going ] [ Designated as safety issue: No ]
|Study Start Date:||April 2002|
Patients with a prior diagnosis of malignancy or refractory cancer will be evaluated in the Medical Oncology Clinic, NCI or Interventional Radiology, NIH Clinical Center. Blood, urine or saliva samples may be collected at the initial visit and at follow-up visits. The specimens will be processed and stored in one or more of these locations for use in research efforts: Laboratory of Tumor Immunology and Biology, Clinical Pharmacology Program, NCI
Frederick, Dr. Tito Fojo s laboratory and Dr. Jane Trepel s Laboratory.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034216
|Contact: Sheri A McMahon, R.N.||(301) firstname.lastname@example.org|
|Contact: James L Gulley, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937|
|Principal Investigator:||James L Gulley, M.D.||National Cancer Institute (NCI)|